Tutorials
Launch Event Recording: Green Inhaler QI Project
Completing this QI Project
Demonstration patient consultation: COPD review
Demonstration patient consultation: Asthma review
Green Inhaler QI Project
This programme supports practices to complete the mandatory QIF Green Agenda QI project, starting April 2023. The aim of the QI project is to reduce the use of inhalers with high Global Warming Potential, and reduce the over-reliance of Short Acting Beta Agonist (SABA) reliever inhalers.
The project is worth 35 QIF points (average £6.5k) per practice, and is to be completed by April 2024.
Guidelines
All-Wales Adult Asthma Management and Prescribing Guideline |
|---|
All-Wales COPD Management and Prescribing Guideline |
|---|
Resources
 |
|---|
QIF Green Inhaler QI Project
QMS Contract 2022/2023 – Mandatory
 |
|---|
Slides for practices – internal discussion
For internal discussion about this Green Inhaler QI Project.
|
|---|
Green Inhaler QI Project – template form
A suggested template for recording your practice’s progress against the QI project, for submission to your healthboard on completion
|
|---|
NHS Wales Decarbonisation Strategic Delivery Plan
How NHS Wales can play its part in the recovery and its commitment to the Wellbeing of Future Generations (Wales) Act 2015.
|
|---|
Template letter – asthma review invitation (EN)
Inviting patients for a review of their asthma, particularly those who are high SABA users.
|
|---|
Template letter – asthma review invitation (CY)
Inviting patients for a review of their asthma, particularly those who are high SABA users. Letter in Welsh.
|
|---|
NICE Patient Decision Support Aid
NICE have produced a patient decision aid to support inhaler choice for patients and HCPs
QI Projects
Green Inhaler QI Project
Please note - this is a supporting toolkit for the QIF Mandatory Green Inhaler QI Project
0%
completed
completed
Overview of the project
This QI project will reduce the environmental impact of respiratory prescribing and help achieve the targets of the NHS Wales Decarbonisation Strategic Delivery Plan
Why is it important?
Overuse of SABA inhalers, in asthma, is associated with increased risk of exacerbation and mortality as well as contributing hugely to the NHS carbon footprint.
